MIRM - Company ID 0001759425
The table below shows Mirum Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $324.91M | $282.02M | $228.12M | $211.82M | $222.97M | $233.25M |
| Short-term investments | $61.35M | $93.53M | $76.43M | $65.85M | $61.48M | $45.13M |
| Receivables | $133.11M | $107.13M | $106.84M | $95.85M | $68.53M | $60.43M |
| Inventory | $25.52M | $24.02M | $22.94M | $22.42M | $21.59M | $20.44M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $569.44M |
| $530.58M |
| $453.40M |
| $410.82M |
| $386.63M |
| $367.83M |
| Property, plant & equipment | $2.41M | $1.28M | $1.18M | $1.11M | $1.21M | $1.10M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $890.92M | $785.12M | $725.83M | $690.25M | $667.89M | $660.75M |
| Accounts payable | $59.40M | $12.17M | $17.66M | $11.64M | $9.54M | $9.84M |
| Total current liabilities | $272.82M | $160.36M | $144.80M | $127.58M | $115.75M | $112.31M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $648.42M | $493.07M | $470.67M | $456.99M | $435.87M | $431.77M |
| Retained earnings | -$1.46B | -$661.81M | -$664.72M | -$658.86M | -$620.39M | -$606.16M |
| Total equity | $242.49M | $292.05M | $255.16M | $233.26M | $232.02M | $228.99M |